📰 Eric Easom News
Eric Easom News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Easom. Real-time updates on events, politics, business and more.
March 28, 2024
Phase 2/3 trial in treatment-refractory Mycobacterium avium Complex continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of...
February 13, 2024
MENLO PARK - AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today...
January 30, 2024
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that...
November 9, 2023
Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex lung disease On track to announce Phase 2 clinical data...
November 6, 2023
AN2 Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that...
October 18, 2023
License enables advancement of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical studies well underway in
October 18, 2023
License enables advancement of AN2-502998 , a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical studies well underway in...
October 16, 2023
Key Insights The considerable ownership by individual investors in AN2 Therapeutics indicates that they collectively...
September 13, 2023
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries as...